Related Organisms
Part of Vaccines
Identifying naturally occurring related pathogens that may provide cross-protective immunity to dangerous diseases.
Why This Matters
Jenner’s discovery was not that vaccines could be created — it was that nature had already created one. Cowpox existed. It infected humans mildly. And it protected against smallpox completely. The cowpox-smallpox relationship is the model case of what every vaccine researcher since has sought: a related organism that stimulates immunity without causing the disease you fear.
These natural relationships are not accidents. Within any pathogen family, related species share structural proteins that the immune system recognizes as similar. An immune response against one member of the family provides partial or complete protection against related members. The closer the genetic relationship, the more likely cross-protection is to be complete.
Finding and identifying related organisms with cross-protective potential is one of the most valuable avenues for vaccine development in a rebuilding context. It requires knowledge of pathogen ecology — which organisms exist in local animals, which of those occasionally infect humans, and which cause only mild human disease. This knowledge is assembled from careful observation of disease patterns in animals and humans, not from laboratory equipment.
Principles of Cross-Protection
Shared antigens: Cross-protection depends on the immune system encountering antigens from organism A that are similar enough to antigens on organism B that the response to A confers protection against B.
How similar do antigens need to be? This varies. Cowpox and smallpox are roughly 96% genomically similar and share the surface proteins critical for cell entry. This produces complete cross-protection. Two organisms 70% similar might produce partial protection (reduced severity rather than complete prevention). Organisms sharing only 30% genetic content may share incidental antigens that provide limited cross-reactivity.
The ideal cross-protective organism:
- Genetically closely related to the dangerous pathogen
- Infects humans but causes only mild or self-limiting disease
- Stably attenuated — does not revert to causing severe disease
- Can be grown in accessible host species
- Induces immune response to antigens shared with the dangerous pathogen
Orthopoxvirus Family
The most important example of cross-protective related organisms.
Family members:
| Virus | Primary Host | Human Disease |
|---|---|---|
| Variola major | Humans | Smallpox (30% mortality) |
| Variola minor | Humans | Alastrim (1% mortality) |
| Vaccinia | Unknown (extinct progenitor?) | Mild, localized infection |
| Cowpox | Rodents (cats, cattle incidentally) | Mild skin lesions |
| Horsepox | Horses (possibly extinct) | Mild |
| Camelpox | Camels | Mild skin lesions in humans |
| Monkeypox | Squirrels, primates | Moderate disease (1-10% mortality) |
| Buffalopox | Buffalo | Mild in humans |
Key relationships:
- Any orthopoxvirus infection or vaccination provides cross-protection against smallpox
- Cowpox vaccination provides 80-95% protection against smallpox
- Variola minor infection provides protection against variola major (used for deliberate inoculation before Jenner’s work)
- Monkeypox immunity is conferred by smallpox vaccination (important as monkeypox resurges in smallpox-naive populations)
Practical implication: In a post-smallpox-eradication world (where vaccination has ceased), cowpox or other orthopoxviruses circulating in rodents and domesticated animals represent potential natural vaccine sources if smallpox or monkeypox threatens again. Identifying active orthopoxvirus infections in local animals — by characteristic pustular lesions — could provide source material.
Mycobacterium Family
Tuberculosis (Mycobacterium tuberculosis) is protected against by BCG vaccine, which is a live attenuated strain of Mycobacterium bovis — cattle tuberculosis.
Relationship: M. tuberculosis and M. bovis are closely related members of the Mycobacterium tuberculosis complex. They share most of their genome and many surface antigens. M. bovis normally infects cattle but can infect humans (causing tuberculosis, often intestinal via infected milk).
BCG (M. bovis, Bacillus Calmette-Guérin strain) was attenuated through 230 serial passages on ox bile-glycerol-potato medium over 13 years. The resulting strain lost its virulence but retained its ability to stimulate cellular immunity.
Other mycobacteria: Environmental mycobacteria (M. avium complex, M. gordonae, others) are widespread in soil and water. They do not cause disease in healthy individuals but stimulate some level of cross-immunity with tuberculosis. This partially explains why tuberculosis burden varies by geography even before BCG vaccination — areas with high environmental mycobacterial exposure have some degree of natural background immunity.
Leprosy: M. leprae (leprosy) is also in the mycobacterium family. BCG vaccination provides partial protection against leprosy (approximately 50% in some studies), though the protection is variable by geography, suggesting environmental mycobacteria modify the response.
Vibrio Family
Cholera (Vibrio cholerae O1 and O139) has cross-reactive relationships within the Vibrio genus.
El Tor biotype: Two biotypes of V. cholerae O1 cause cholera: Classical (now extinct) and El Tor (current). Infection with El Tor provides cross-protection against Classical and vice versa. Natural infection with mild or sub-clinical El Tor strains may provide some protection.
Non-O1 Vibrio cholerae: V. cholerae strains outside serogroup O1/O139 do not cause epidemic cholera but colonize human intestines. They share some antigens with epidemic strains. Population exposure to non-O1 strains may contribute to variable cholera susceptibility.
Vibrio mimicus: Closely related to V. cholerae, occasionally causes mild diarrheal illness. Shares some surface antigens. Not studied sufficiently as a cross-protection candidate.
Brucella and Related Organisms
Brucellosis affects cattle (B. abortus), sheep/goats (B. melitensis), pigs (B. suis), and other animals, with all species capable of infecting humans. Between animal species, cross-immunity exists: infection with B. abortus provides partial protection against B. melitensis in cattle.
Veterinarians and farmers working with infected livestock who become subclinically infected with attenuated strains may develop some protection — this was observed empirically in occupational groups before vaccination existed.
Rev1 vaccine for small ruminants: An attenuated B. melitensis strain (Rev1) used to vaccinate goats and sheep against brucellosis can infect humans accidentally during vaccination. This causes mild brucellosis-like illness but confers immunity. Not recommended as intentional human vaccination due to disease risk and potential for persistence, but illustrates the cross-protective principle.
Salmonella Family
Typhoid fever (S. typhi) and non-typhoidal Salmonella (S. typhimurium, S. enteritidis) are closely related but produce very different disease severity. Non-typhoidal Salmonella causes gastroenteritis; S. typhi causes systemic typhoid fever with 10-30% untreated mortality.
The cross-protective relationship between these species is limited — they share some O antigens but differ significantly in virulence determinants. Natural infection with non-typhoidal Salmonella does not reliably protect against typhoid.
However, attenuated S. typhi strains have been used as oral typhoid vaccines (Ty21a) — this represents attenuation within the species rather than cross-protection from a related species.
Identifying Potential Cross-Protective Relationships
When facing a new or resurgent pathogen, a systematic approach to identifying related organisms:
Step 1: Taxonomic survey What family does the pathogen belong to? What other members of this family affect local animals or humans? This requires access to basic taxonomy references or practitioners with natural history knowledge.
Step 2: Clinical observation Who in the community has not gotten the disease despite apparent exposure? What are they exposed to that others are not? Occupational groups (farmers, butchers, herders) with high animal contact may show different disease rates from the general population.
Step 3: Experimental epidemiology If cross-protection is suspected, compare disease rates between people with and without exposure to the suspected related organism. This is observational evidence, not conclusive, but can guide decisions.
Step 4: Cautious testing If a related organism is identified as a candidate, follow the same safety and efficacy testing sequence required for any vaccine candidate: animal safety tests, dose determination, small human trials with close monitoring.
Natural cross-protection candidates are not automatically safe. Cowpox was not without risk (and caused progressive vaccinia in immunocompromised individuals). The principle is valuable; the implementation still requires careful testing.